157 related articles for article (PubMed ID: 2513643)
41. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole.
Berstad AE; Hatlebakk JG; Maartmann-Moe H; Berstad A; Brandtzaeg P
Gut; 1997 Dec; 41(6):740-7. PubMed ID: 9462205
[TBL] [Abstract][Full Text] [Related]
42. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.
Eriksson S; Långström G; Rikner L; Carlsson R; Naesdal J
Eur J Gastroenterol Hepatol; 1995 May; 7(5):467-75. PubMed ID: 7614110
[TBL] [Abstract][Full Text] [Related]
43. The role of omeprazole in healing and prevention of reflux disease.
Klinkenberg-Knol EC
Hepatogastroenterology; 1992 Feb; 39 Suppl 1():27-30. PubMed ID: 1577392
[TBL] [Abstract][Full Text] [Related]
44. Omeprazole in acute and long-term treatment of Asian patients with peptic ulcer refractory to H2-antagonists.
Chelvam P; Wong EC
J Gastroenterol Hepatol; 1989; 4 Suppl 2():75-81. PubMed ID: 2577478
[TBL] [Abstract][Full Text] [Related]
45. Multiple gastric carcinoids and endocrine cell micronests in type A gastritis: Nuclear morphometric and immunohistochemical analysis.
Iwai K; Yao T; Nakamura S; Matsumoto T; Nishiyama K; Iida M; Tsuneyoshi M
Oncol Rep; 2005 Mar; 13(3):397-404. PubMed ID: 15706407
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the effects of Helicobacter pylori eradication therapy on gastric antral epithelial hyperproliferation: a prospective six-month follow-up study.
Demiray M; Gulten M; Manavoglu O; Evrensel T; Ulukaya E; Yerci O; Kanat O; Kurt E; Arslan M; Gonullu G; Demiray H; Gulten T; Memik F
Hepatogastroenterology; 2004; 51(59):1531-5. PubMed ID: 15362794
[TBL] [Abstract][Full Text] [Related]
47. Proton pump inhibitors, enterochromaffin-like cell growth and Helicobacter pylori gastritis.
Solcia E; Villani L; Luinetti O; Fiocca R
Aliment Pharmacol Ther; 1993; 7 Suppl 1():25-8, discussion 29-31. PubMed ID: 8490076
[TBL] [Abstract][Full Text] [Related]
48. Morphology and pathogenesis of endocrine hyperplasias, precarcinoid lesions, and carcinoids arising in chronic atrophic gastritis.
Solcia E; Fiocca R; Villani L; Gianatti A; Cornaggia M; Chiaravalli A; Curzio M; Capella C
Scand J Gastroenterol Suppl; 1991; 180():146-59. PubMed ID: 2042031
[TBL] [Abstract][Full Text] [Related]
49. Omeprazole in H2 receptor antagonist-resistant reflux esophagitis.
Marciano-D'Amore DA; Paterson WG; Da Costa LR; Beck IT
J Clin Gastroenterol; 1990 Dec; 12(6):616-20. PubMed ID: 1979984
[TBL] [Abstract][Full Text] [Related]
50. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
Haga Y; Nakatsura T; Shibata Y; Sameshima H; Nakamura Y; Tanimura M; Ogawa M
Dig Dis Sci; 1998 Feb; 43(2):253-7. PubMed ID: 9512115
[No Abstract] [Full Text] [Related]
51. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
Park KN; Hahm JS; Kim HJ
Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
[TBL] [Abstract][Full Text] [Related]
52. Clinical experience with omeprazole: assessment of efficacy and safety.
Walan A
J Gastroenterol Hepatol; 1989; 4 Suppl 2():27-33. PubMed ID: 2491359
[TBL] [Abstract][Full Text] [Related]
53. Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses.
Gremse DA
Expert Opin Pharmacother; 2001 Oct; 2(10):1663-70. PubMed ID: 11825309
[TBL] [Abstract][Full Text] [Related]
54. Omeprazole or ranitidine in long-term treatment of reflux esophagitis. The Scandinavian Clinics for United Research Group.
Hallerbäck B; Unge P; Carling L; Edwin B; Glise H; Havu N; Lyrenäs E; Lundberg K
Gastroenterology; 1994 Nov; 107(5):1305-11. PubMed ID: 7926494
[TBL] [Abstract][Full Text] [Related]
55. Histologic changes in type A chronic atrophic gastritis indicating increased risk of neuroendocrine tumor development: the predictive role of dysplastic and severely hyperplastic enterochromaffin-like cell lesions.
Vanoli A; La Rosa S; Luinetti O; Klersy C; Manca R; Alvisi C; Rossi S; Trespi E; Zangrandi A; Sessa F; Capella C; Solcia E
Hum Pathol; 2013 Sep; 44(9):1827-37. PubMed ID: 23642738
[TBL] [Abstract][Full Text] [Related]
56. Omeprazole: implications for therapy of peptic ulcer and reflux oesophagitis.
Bium AL
Digestion; 1989; 44 Suppl 1():87-91. PubMed ID: 2691314
[TBL] [Abstract][Full Text] [Related]
57. [Comment on the contribution: "Effect of omeprazole on serum gastrin levels: influence of age and sex" by Koop et al].
Miederer SE
Z Gastroenterol; 1991 Apr; 29(4):177-8. PubMed ID: 1866976
[No Abstract] [Full Text] [Related]
58. Gastrin and gastric enterochromaffin-like cell carcinoids in the rat.
Carlsson E; Havu N; Mattsson H; Ekman L
Digestion; 1990; 47 Suppl 1():17-23; discussion 49-52. PubMed ID: 2093010
[TBL] [Abstract][Full Text] [Related]
59. Omeprazole and ranitidine, antisecretagogues with different modes of action, are equally effective in causing hyperplasia of enterochromaffin-like cells in rat stomach.
Ryberg B; Bishop AE; Bloom SR; Carlsson E; Håkanson R; Larsson H; Mattsson H; Polak JM; Sundler F
Regul Pept; 1989 May; 25(2):235-46. PubMed ID: 2756157
[TBL] [Abstract][Full Text] [Related]
60. Treatment of reflux oesophagitis resistant to H2-receptor antagonists.
Klinkenberg-Knol EC; Meuwissen SG
Digestion; 1989; 44 Suppl 1():47-53. PubMed ID: 2575061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
